FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996626346> ?p ?o ?g. }

• W1996626346 abstract "Increasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as tyrosine kinase inhibitors (TKIs). We hypothesized that TKIs would have differential effects on CSC populations depending on their mechanism of action (anti-proliferative vs. anti-angiogenic).We exposed human sarcoma cell lines to sorafenib, regorafenib, and pazopanib and assessed cell viability and expression of CSC markers (ALDH, CD24, CD44, and CD133). We evaluated survival and CSC phenotype in mice harboring sarcoma metastases after TKI therapy. We exposed dissociated primary sarcoma tumors to sorafenib, regorafenib, and pazopanib, and we used tissue microarray (TMA) and primary sarcoma samples to evaluate the frequency and intensity of CSC markers after neoadjuvant therapy with sorafenib and pazopanib. Parametric and non-parametric statistical analyses were performed as appropriate.After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and regorafenib were cytotoxic to sarcoma cell lines (P < 0.05), with a corresponding 1.4 - 2.8 fold increase in ALDHbright cells from baseline (P < 0.05). In contrast, we observed negligible effects on viability and CSC sub-populations with pazopanib. At low doses, there was progressive CSC enrichment in vitro after longer term exposure to sorafenib although the anti-proliferative effects were attenuated. In vivo, sorafenib improved median survival by 11 days (P < 0.05), but enriched ALDHbright cells 2.5 - 2.8 fold (P < 0.05). Analysis of primary human sarcoma samples revealed direct cytotoxicity following exposure to sorafenib and regorafenib with a corresponding increase in ALDHbright cells (P < 0.05). Again, negligible effects from pazopanib were observed. TMA analysis of archived specimens from sarcoma patients treated with sorafenib demonstrated significant enrichment for ALDHbright cells in the post-treatment resection specimen (P < 0.05), whereas clinical specimens obtained longitudinally from a patient treated with pazopanib showed no enrichment for ALDHbright cells (P > 0.05).Anti-proliferative TKIs appear to enrich for sarcoma CSCs while anti-angiogenic TKIs do not. The rational selection of targeted therapies for sarcoma patients may benefit from an awareness of the differential impact of TKIs on CSC populations." @default.
• W1996626346 created "2016-06-24" @default.
• W1996626346 creator A5020360938 @default.
• W1996626346 creator A5021779730 @default.
• W1996626346 creator A5034656359 @default.
• W1996626346 creator A5039178629 @default.
• W1996626346 creator A5042070203 @default.
• W1996626346 creator A5046331134 @default.
• W1996626346 creator A5058265550 @default.
• W1996626346 creator A5062224612 @default.
• W1996626346 creator A5065634805 @default.
• W1996626346 creator A5069430287 @default.
• W1996626346 creator A5079900226 @default.
• W1996626346 creator A5089041781 @default.
• W1996626346 date "2014-10-10" @default.
• W1996626346 modified "2023-09-23" @default.
• W1996626346 title "Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma" @default.
• W1996626346 cites W125341987 @default.
• W1996626346 cites W1576907138 @default.
• W1996626346 cites W1967245224 @default.
• W1996626346 cites W1976208893 @default.
• W1996626346 cites W1994812668 @default.
• W1996626346 cites W2008710706 @default.
• W1996626346 cites W2012619882 @default.
• W1996626346 cites W2018939183 @default.
• W1996626346 cites W2019313509 @default.
• W1996626346 cites W2023316892 @default.
• W1996626346 cites W2038873665 @default.
• W1996626346 cites W2052461136 @default.
• W1996626346 cites W2066362124 @default.
• W1996626346 cites W2069064270 @default.
• W1996626346 cites W2078510083 @default.
• W1996626346 cites W2083174268 @default.
• W1996626346 cites W2083274861 @default.
• W1996626346 cites W2090117256 @default.
• W1996626346 cites W2091423185 @default.
• W1996626346 cites W2093433762 @default.
• W1996626346 cites W2093730290 @default.
• W1996626346 cites W2093778789 @default.
• W1996626346 cites W2096965934 @default.
• W1996626346 cites W2099064703 @default.
• W1996626346 cites W2101776780 @default.
• W1996626346 cites W2104447909 @default.
• W1996626346 cites W2105504936 @default.
• W1996626346 cites W2140765540 @default.
• W1996626346 cites W2156612784 @default.
• W1996626346 cites W2156719617 @default.
• W1996626346 cites W2158627893 @default.
• W1996626346 cites W2159607376 @default.
• W1996626346 cites W2159640574 @default.
• W1996626346 cites W4233669846 @default.
• W1996626346 doi "https://doi.org/10.1186/1471-2407-14-756" @default.
• W1996626346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4200119" @default.
• W1996626346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25301268" @default.
• W1996626346 hasPublicationYear "2014" @default.
• W1996626346 type Work @default.
• W1996626346 sameAs 1996626346 @default.
• W1996626346 citedByCount "21" @default.
• W1996626346 countsByYear W19966263462015 @default.
• W1996626346 countsByYear W19966263462016 @default.
• W1996626346 countsByYear W19966263462017 @default.
• W1996626346 countsByYear W19966263462018 @default.
• W1996626346 countsByYear W19966263462020 @default.
• W1996626346 countsByYear W19966263462023 @default.
• W1996626346 crossrefType "journal-article" @default.
• W1996626346 hasAuthorship W1996626346A5020360938 @default.
• W1996626346 hasAuthorship W1996626346A5021779730 @default.
• W1996626346 hasAuthorship W1996626346A5034656359 @default.
• W1996626346 hasAuthorship W1996626346A5039178629 @default.
• W1996626346 hasAuthorship W1996626346A5042070203 @default.
• W1996626346 hasAuthorship W1996626346A5046331134 @default.
• W1996626346 hasAuthorship W1996626346A5058265550 @default.
• W1996626346 hasAuthorship W1996626346A5062224612 @default.
• W1996626346 hasAuthorship W1996626346A5065634805 @default.
• W1996626346 hasAuthorship W1996626346A5069430287 @default.
• W1996626346 hasAuthorship W1996626346A5079900226 @default.
• W1996626346 hasAuthorship W1996626346A5089041781 @default.
• W1996626346 hasBestOaLocation W19966263461 @default.
• W1996626346 hasConcept C121608353 @default.
• W1996626346 hasConcept C126322002 @default.
• W1996626346 hasConcept C142724271 @default.
• W1996626346 hasConcept C143998085 @default.
• W1996626346 hasConcept C1491633281 @default.
• W1996626346 hasConcept C2776248978 @default.
• W1996626346 hasConcept C2778019345 @default.
• W1996626346 hasConcept C2778256501 @default.
• W1996626346 hasConcept C2778439243 @default.
• W1996626346 hasConcept C2778629024 @default.
• W1996626346 hasConcept C2778695046 @default.
• W1996626346 hasConcept C2779490328 @default.
• W1996626346 hasConcept C2780932548 @default.
• W1996626346 hasConcept C502942594 @default.
• W1996626346 hasConcept C526805850 @default.
• W1996626346 hasConcept C54355233 @default.
• W1996626346 hasConcept C55427017 @default.
• W1996626346 hasConcept C71924100 @default.
• W1996626346 hasConcept C86803240 @default.
• W1996626346 hasConceptScore W1996626346C121608353 @default.
• W1996626346 hasConceptScore W1996626346C126322002 @default.
• W1996626346 hasConceptScore W1996626346C142724271 @default.

• next